Back to top
more

Invacare Corporation (IVC)

(Delayed Data from NYSE)

$7.57 USD

7.57
411,009

+0.33 (4.56%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.57 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Invacare (IVC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of -45.95% and 13.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of -20.45% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of -60.47% and 2.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q3 Earnings Miss Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of -5.84% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 7.44% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Q4 Earnings Top Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of 300% and 6.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Invacare (IVC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of 40.00% and 0.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Invacare (IVC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Invacare (IVC) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Invacare (IVC) stock based on the movements in the options market lately.

New Strong Sell Stocks for August 27th

by Zacks Equity Research

CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021

Invacare (IVC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of -33.33% and 4.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Invacare (IVC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions

by Zacks Equity Research

Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.

Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market

by Zacks Equity Research

Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.

Integra's (IART) Neurosurgery Rebounds Despite Supply Issues

by Zacks Equity Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit

by Zacks Equity Research

According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.

Here's Why You Should Retain Cooper Companies (COO) Now

by Zacks Equity Research

Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.

DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.

Here's Why You Should Buy Align Technology (ALGN) Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on robust international performance and continued portfolio expansion.